Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
Journal of Korean Medical Science 2021³â 36±Ç 14È£ p.107 ~ p.107
±è½ÃÈ£(Kim Si-Ho) - Samsung Changwon Hospital Center for Infection Prevention and Control
À§À¯¹Ì(Wi Yu-Mi) - Sungkyunkwan University School of Medicine Samsung Changwon Hospital Division of Infectious Diseases
À±¼ö¿¬(Yun Su-Yeon) - Samsung Changwon Hospital Center for Infection Prevention and Control
·ùÁ¤¼±(Ryu Jeong-Seon) - Samsung Changwon Hospital Center for Infection Prevention and Control
½ÅÁ¤¹Î(Shin Jung-Min) - Samsung Changwon Hospital Center for Infection Prevention and Control
ÀÌÀºÈñ(Lee Eun-Hui) - Samsung Changwon Hospital Center for Infection Prevention and Control
¼°æÈ(Seo Kyung-Hwa) - Samsung Changwon Hospital Center for Infection Prevention and Control
À̼ºÈñ(Lee Sung-Hee) - Samsung Changwon Hospital Center for Infection Prevention and Control
¹é°æ¶õ(Peck Kyong-Ran) - Sungkyunkwan University School of Medicine Samsung Medical Center Division of Infectious Diseases
Abstract
Coronavirus disease 2019 vaccinations for healthcare workers (HCWs) have begun in South Korea. To investigate adverse events (AEs) of the first dose of each vaccine, any symptom was collected daily for seven days after vaccination in a tertiary hospital. We found that 1,301 of 1,403 ChAdOx1 nCoV-19 recipients and 38 of 80 BNT162b2 recipients reported AEs respectively (90.9% vs. 52.5%): injection-site pain (77.7% vs. 51.2%), myalgia (60.5% vs. 11.2%), fatigue (50.7% vs. 7.5%), headache (47.4% vs. 7.5%), and fever (36.1% vs. 5%; P < 0.001 for all). Young HCWs reported more AEs with ChAdOx1 nCoV-19 than with BNT162b2. No incidences of anaphylaxis were observed. Only one serious AE required hospitalization for serious vomiting, and completely recovered. In conclusion, reported AEs were more common in recipients with ChAdOx1 nCoV-19 than in those with BNT162b2. However, most of the reported AEs were mild to moderate in severity. Sufficient explanation and preparation for expected AEs required to promote widespread vaccination.
Å°¿öµå
Coronavirus Disease 2019, Vaccine, Adverse Event, ChAdOx1 nCoV-19 Vaccine, BNT162b2 mRNA COVID-19 Vaccine
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This study found that 1,301 of 1,403 ChAdOx1 nCoV-19 recipients and 38 of 80 BNT162b2 recipients reported AEs respectively (90.9% vs. 52.5%): injection-site pain (77.7% vs. 51.2%), myalgia (60.5% vs. 11.2%), fatigue (50.7% vs. 7.5%), headache (47.4% vs. 7.5%), and fever (36.1% vs. 5%; P < 0.001 for all). Young HCWs reported more AEs with ChAdOx1 nCoV-19 than with BNT162b2. ; the incidence of AEs was a much higher in recipients with the ChAdOx1 nCoV-19 vaccine than in those with the BNT162b2 vaccine.